Accéder au contenu
Merck
  • LPS-induced proNGF synthesis and release in the N9 and BV2 microglial cells: a new pathway underling microglial toxicity in neuroinflammation.

LPS-induced proNGF synthesis and release in the N9 and BV2 microglial cells: a new pathway underling microglial toxicity in neuroinflammation.

PloS one (2013-09-17)
Li Duan, Bei-Yu Chen, Xiao-Long Sun, Zhuo-Jing Luo, Zhi-Ren Rao, Jing-Jie Wang, Liang-Wei Chen
RÉSUMÉ

While aberrant activation of microglial cells was evidently involved in neuroinflammation and neurotoxicity in the neurodegenerative diseases such as Alzheimer's and Parkinson's disease, objective of study was to address if activated microglias deliver their effect by releasing pro-neurotrophins. By in vitro culture of N9 and BV2 cell lines and lipopolysaccharide (LPS) stimulation model, generation and release of proNGF, proBDNF and MMP-9 was studied in the activated microglial cells by immunocytochemistry, western blotting and bioassay methods. Activation of microglial cells was observed with obvious increasing iba1-immunoreactivity following LPS stimulation in cell culture. Synthesis and up-regulation of proNGF protein significantly occurred in N9 and BV2 cells 12h-48h after LPS exposure, whereas no significant changes of proBDNF and MMP9 were observed in these microglial cell lines with LPS insult. More interestingly, extracellular release or secretion of proNGF molecule was also detected in culture medium of N9 cells after LPS stimulation. Finally, bioassay using MTT, Hoechst/PI and TUNEL staining in SH-SY5Y cells further confirmed that proNGF treatment could result in apoptotic cell death but it did not significantly influence cell viability of SH-SY5Y cells. This in vitro study revealed LPS-stimulated proNGF synthesis and release in activated N9/BV2 microglial cell lines, also suggesting that proNGF may appeal a new pathway or possible mechanism underlying microglial toxicity in the neuroinflammation and a potential target for therapeutic manipulation of the neurodegenerative diseases.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anti-Nerve Growth Factor 2.5S antibody produced in rabbit, fractionated antiserum, buffered aqueous solution
Sigma-Aldrich
Anti-Pro-BDNF antibody produced in rabbit, affinity isolated antibody, lyophilized powder
Sigma-Aldrich
Anti-MMP-9 antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Anti-Pro-NGF antibody produced in rabbit, affinity isolated antibody, lyophilized powder